for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AzurRx BioPharma Inc

AZRX.OQ

Latest Trade

1.00USD

Change

-0.01(-0.99%)

Volume

67,751

Today's Range

0.99

 - 

1.02

52 Week Range

0.86

 - 

3.75

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.01
Open
1.00
Volume
67,751
3M AVG Volume
5.16
Today's High
1.02
Today's Low
0.99
52 Week High
3.75
52 Week Low
0.86
Shares Out (MIL)
26.10
Market Cap (MIL)
26.10
Forward P/E
-1.24
Dividend (Yield %)
--

Latest Developments

More

AzurRx BioPharma Says On Track To Announce Final Data Analysis Of Option Study In September 2019

Azurrx Biopharma Announces Proposed Public Offering Of Common Stock

AzurRx BioPharma Announces Initiation Of Phase 2 Clinical Study For Ms1819-Sd

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AzurRx BioPharma Inc

AzurRx BioPharma, Inc. is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company's product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).

Industry

Biotechnology & Drugs

Contact Info

760 Parkside Ave Ste 304

+1.646.6997855

https://www.azurrx.com/

Executive Leadership

Edward J. Borkowski

Independent Chairman of the Board

Johan M. Spoor

President, Chief Executive Officer, Director

Maged S. Shenouda

Chief Financial Officer, Director

James E. Pennington

Chief Medical Officer

Charles J. Casamento

Independent Director

Key Stats

1.60 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-2.240

2017

-1.040

2018

-0.880

2019(E)

-0.808
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
7.16
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
64.51
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-260.32
Return on Equity (TTM)
-152.64

Latest News

BRIEF-Azurrx Biopharma Enrolls New Patients For Phase IIA Study Of MS1819-SD

* AZURRX BIOPHARMA ANNOUNCES ENROLLMENT OF THREE NEW PATIENTS FOR ITS PHASE IIA STUDY OF MS1819-SD Source text for Eikon: Further company coverage:

BRIEF-AzurRx BioPharma Announces Receipt of Required Approvals to Add French Clinical Site for its Phase IIa Study of MS1819-SD

* AZURRX BIOPHARMA ANNOUNCES RECEIPT OF REQUIRED APPROVALS TO ADD FRENCH CLINICAL SITE FOR ITS PHASE IIA STUDY OF MS1819-SD FOR EXOCRINE PANCREATIC INSUFFICIENCY

BRIEF-AzurRx Biopharma receives $2 mln in proceeds from exercise of warrants

* AZURRX BIOPHARMA RECEIVES $2 MILLION IN PROCEEDS FROM EXERCISE OF WARRANTS

BRIEF-AzurRx Biopharma files for mixed shelf offering of up to $10 mln

* AzurRx Biopharma Inc files for mixed shelf offering of up to $10 million - SEC filing Source text: [http://bit.ly/2z4AEuv] Further company coverage:

BRIEF-Azurrx Biopharma, Mayoly Spindler announce IMPD submission

* Azurrx Biopharma and Mayoly Spindler announce MS1819-SD investigational medicinal product dossier (IMPD) submission

BRIEF-AzurRx BioPharma files for stock shelf of upto $10 mln

* Azurrx biopharma inc files for stock shelf of upto $10 million - sec filing Source text for Eikon: (http://bit.ly/2hChpOb) Further company coverage:

BRIEF-AzurRx Biopharma announces positive MS1819-SD Phase II data in exocrine pancreatic insufficiency

* AzurRx Biopharma and Mayoly-Spindler announce positive MS1819-SD phase II data in exocrine pancreatic insufficiency (epi)

BRIEF-Azurrx announces appointment of Chief Financial Officer

* Azurrx announces appointment of Maged Shenouda as Chief Financial Officer Source text for Eikon: Further company coverage:

BRIEF-Azurrx reaches 6th patient enrollment of midstage trial for pancreas drug

* Azurrx reaches 6th patient enrollment of Phase IIA trial of MS1819 for treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis

BRIEF-Azurrx Biopharma enters into sublicense agreement with Transchem

* Azurrx Biopharma Inc - on August 7, 2017, Azurrx Biopharma, Inc entered into a sublicense agreement with Transchem, Inc. - sec filing

BRIEF-Azurrx Biopharma Inc files for offering of 5.9 million shares of common stock

* Azurrx Biopharma Inc files for offering of 5.9 million shares of common stock by the selling stockholders Source text: (http://bit.ly/2uhef9X) Further company coverage:

BRIEF-Azurrx Biopharma on April 11 entered securities purchase agreement with Lincoln Park Capital Fund

* Azurrx Biopharma Inc- on April 11 entered securities purchase agreement with Lincoln Park Capital Fund, LLC - sec filing

BRIEF-AzurRx provides update on MS1819 phase II trial

* AzurRx Biopharma Inc - Early results indicate that MS1819 exhibits a favorable safety profile Source text for Eikon: Further company coverage:

BRIEF-Azurrx announces addition of Charles Casamento to the board

* Azurrx announces addition of Charles J Casamento to the board of directors Source text for Eikon: Further company coverage:

BRIEF-AzurRx BioPharma, Mayoly-Spindler initiate phase II clinical trial of MS1819-SD

* Azurrx biopharma-mayoly spindler grants co marketing rights for recombinant lipase in various geographies, including exclusive rights for north america

BRIEF-Azurrx Biopharma reports pricing of IPO

* Says initial public offering of 960,000 common shares priced at $5.50 per share Source text for Eikon: Further company coverage:

BRIEF-Azurrx Biopharma Inc sees IPO of 1.2 mln shares priced at $5.50 per share

* Azurrx Biopharma Inc sees IPO of 1.2 mln shares priced at $5.50 per share, below previously stated range of $6-$8 per share Source text http://bit.ly/2d2EZmg Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up